Abstract
In August 2011 brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibody–drug conjugate, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with Hodgkin's lymphoma and patients with systemic anaplastic large cell lymphoma (ALCL).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Cancer Cell International Open Access 13 August 2022
-
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Signal Transduction and Targeted Therapy Open Access 22 March 2022
-
New systemic treatment options in mycosis fungoides and Sézary syndrome
memo - Magazine of European Medical Oncology Open Access 20 May 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Alley, S. C, Okeley, N. M. & Senter, P. D. Antibody–drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14, 529–537 (2010).
Younes, A. CD30-targeted antibody therapy. Curr. Opin. Oncol. 23, 587–593 (2011).
Wahl, A. F. et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 62, 3736–3742 (2002).
Francisco, J. A. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458–1465 (2003).
Doronina, S. O. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotech. 21, 778–784 (2003).
US Food and Drug Administration. FDA labeling information — Adcetris. FDA website [online], (2011).
Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812–1821 (2010).
Bartlett, N. L. et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann. Oncol. 18, 1071–1079 (2007).
Gallamini, A. et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25, 3746–3752 (2007).
Weihrauch, M. R. et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 65, 5516–5519 (2005).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Anas Younas has received research support and/or honoraria from Seattle Genetics, Sanofi-Aventis, Novartis, Genentech, Plexxikon, Celgene, Gilead and Merck.
Rights and permissions
About this article
Cite this article
Younes, A., Yasothan, U. & Kirkpatrick, P. Brentuximab vedotin. Nat Rev Drug Discov 11, 19–20 (2012). https://doi.org/10.1038/nrd3629
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3629
This article is cited by
-
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Cancer Cell International (2022)
-
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Signal Transduction and Targeted Therapy (2022)
-
Cathepsin B-responsive prodrugs for cancer-targeted therapy: Recent advances and progress for clinical translation
Nano Research (2022)
-
Unlocking the potential of antibody–drug conjugates for cancer therapy
Nature Reviews Clinical Oncology (2021)
-
New systemic treatment options in mycosis fungoides and Sézary syndrome
memo - Magazine of European Medical Oncology (2020)
